Schweitzer P
Division of Cardiology, Department of Medicine, Beth Israel Medical Center and Albert Einstein College ofMedicine, New York, USA.
Vnitr Lek. 2006 Dec;52(12):1185-9.
The management of ventricular tachyarrhythmias and prevention of sudden cardiac death after acute myocardial infarction (AMI) underwent important evolution. In the CAST study, encanaide and other antiarrhythmic drugs were not only ineffective but also increased mortality after myocardial infarction. Amiodarone had some beneficial effect on arrhythmic events without improving survival, and ICDs failed to improve outcome early after AMI. In comparison, short and long term survival benefits of beta blockers, angiotensine converting enzyme inhibitors and aldosterone antagonists after AMI is well established. This review discusses the role of non-arrhythmic therapy in the prevention of ventricular tachyarrhythmia's and sudden cardiac death after AMI.
急性心肌梗死(AMI)后室性快速性心律失常的管理及心脏性猝死的预防经历了重大演变。在CAST研究中,恩卡胺和其他抗心律失常药物不仅无效,还增加了心肌梗死后的死亡率。胺碘酮对心律失常事件有一定益处,但未改善生存率,而植入式心脏复律除颤器(ICD)在AMI早期未能改善预后。相比之下,β受体阻滞剂、血管紧张素转换酶抑制剂和醛固酮拮抗剂在AMI后的短期和长期生存益处已得到充分证实。本综述讨论了非心律失常治疗在预防AMI后室性快速性心律失常和心脏性猝死中的作用。